NADAC acquisition cost data for AJOVY 225 MG/1.5 ML AUTOINJECT. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 51759020210 | $427.41 | 2022-01-01 | Rx |
| 51759020222 | $427.73 | 2022-01-19 | Rx |
| 51759020210 | $427.41 | 2022-01-01 | Rx |
| 51759020210 | $427.41 | 2022-01-01 | Rx |
| 51759020222 | $427.73 | 2022-01-19 | Rx |
| 51759020210 | $427.41 | 2022-01-01 | Rx |
| 51759020222 | $427.73 | 2022-01-19 | Rx |
| 51759020210 | $427.41 | 2022-01-01 | Rx |
| 51759020222 | $427.73 | 2022-01-19 | Rx |
| 51759020210 | $427.41 | 2022-01-01 | Rx |
Generic: Fremanezumab-Vfrm | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | N/A | N/A | N/A | N/A |
| 2020 | $5.2M | 6,841 | 2,641 | $415.25 |
| 2021 | $27.3M | 34,263 | 8,321 | $430.34 |
| 2022 | $48.5M | 55,495 | 12,141 | $451.03 |
| 2023 | $62.6M | 69,530 | 14,658 | $466.57 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $6.1M | 8,460 | 1,705 |
| New York | $5.2M | 5,936 | 1,250 |
| Pennsylvania | $3.7M | 4,079 | 844 |
| Ohio | $3.6M | 4,081 | 853 |
| Florida | $3.5M | 3,504 | 775 |
| North Carolina | $2.8M | 2,768 | 652 |
| Texas | $2.7M | 2,764 | 660 |
| Michigan | $2.0M | 2,192 | 489 |
| Massachusetts | $1.9M | 1,874 | 423 |
| Georgia | $1.8M | 1,915 | 408 |
| Illinois | $1.5M | 1,556 | 368 |
| Kentucky | $1.5M | 1,511 | 350 |
| Tennessee | $1.5M | 1,547 | 339 |
| Wisconsin | $1.4M | 1,608 | 330 |
| Arizona | $1.4M | 1,470 | 357 |
| Colorado | $1.4M | 1,828 | 365 |
| New Jersey | $1.3M | 1,256 | 267 |
| Indiana | $1.3M | 1,213 | 284 |
| Virginia | $1.2M | 1,253 | 280 |
| Missouri | $1.1M | 1,204 | 288 |
| South Carolina | $1.1M | 1,019 | 226 |
| Louisiana | $1.1M | 1,208 | 257 |
| Maryland | $1.1M | 1,156 | 280 |
| Washington | $1.0M | 1,265 | 259 |
| Minnesota | $1.0M | 1,106 | 234 |
| Iowa | $851.2K | 856 | 198 |
| Connecticut | $836.6K | 866 | 175 |
| Alabama | $827.4K | 950 | 198 |
| Utah | $616.7K | 751 | 172 |
| Oregon | $592.3K | 847 | 164 |
| Delaware | $520.3K | 565 | 99 |
| New Hampshire | $518.3K | 604 | 127 |
| Oklahoma | $513.9K | 604 | 123 |
| Kansas | $487.5K | 544 | 102 |
| Idaho | $485.0K | 518 | 117 |
| West Virginia | $470.2K | 528 | 111 |
| Vermont | $411.5K | 286 | 70 |
| Maine | $411.5K | 393 | 83 |
| Mississippi | $407.8K | 463 | 107 |
| Nevada | $366.1K | 418 | 97 |
| Hawaii | $309.3K | 426 | 81 |
| Arkansas | $297.9K | 292 | 73 |
| Nebraska | $270.8K | 362 | 76 |
| New Mexico | $249.3K | 251 | 55 |
| Rhode Island | $198.5K | 189 | 50 |
| Puerto Rico | $194.9K | 270 | 38 |
| Montana | $151.3K | 154 | 31 |
| Alaska | $139.8K | 139 | 30 |
| District of Columbia | $128.0K | 153 | 39 |
| South Dakota | $112.6K | 120 | 37 |
| Wyoming | $81.7K | 90 | 19 |
| North Dakota | $71.4K | 92 | 18 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.